Agomelatine is a melatonergic antidepressant developed by the pharmaceutical company Servier. It is marketed for the treatment of major depressive disorder and has been reported to not produce discontinuation syndrome and have no sexual side effects compared to SSRIs, SNRIs and the older tricyclic antidepressants. Agomelatine may also have positive effects on sleep.
Agomelatine is a new antidepressant with selective agonist actions at melatonin receptors and selective antagonist action at serotonin 5HT-2C receptors.
Agomelatine can help regulate your'body clock' (circadian rhythm) with positive benefits on mood and sleepin depression Agomelatine is used in the treatment of depression or to help prevent depression returning, and isonly available with a doctor's prescription. The symptoms of depression vary from one person toanother, but commonly include persistent sadness, loss of interest in favourite activities, feelings of worthlessness, sleep problems, feeling of being slowed down, feelings of anxiety or changes in appetite and weight. Changes in your daily sleep and appetite patterns are examples of disturbances of your body clock that occur commonly indepression.
Agomelatine is a melatoninergic agonist and selective antagonist of 5-HT2C receptors, and has been shown to be active in several animal models of depression. Agomelatine (S20098) displayed pKi values of 6.4 oraz 6.2 at native (porcine) and cloned, człowiek (h)5-hydroxytryptamine (5-HT)2C receptors, odpowiednio.
